Thymosin Alpha-1 is a thymic immune-modulating peptide studied across four decades of human trials.

The short version

Thymosin Alpha-1 is a tiny natural protein your body makes — a string of 28 building blocks (amino acids) released by the thymus, the small gland behind your breastbone that trains your immune cells. It does not build muscle and it is not a growth or performance peptide. Instead, it acts like a coach for the immune system: it wakes up the alarm-and-messenger cells (called dendritic cells) and helps T-cells (the body's targeted defenders) mature and do their job. Doctors abroad use a lab-made, identical copy called thymalfasin mainly for long-term hepatitis (a liver virus) and to support a worn-down immune system. It is approved in roughly 35 countries but not approved for sale in the United States. The honest headline: the strongest results are in chronic viral hepatitis, but the largest, most careful sepsis (severe blood infection) trial showed no benefit. What people report — including the downsides — is on the effects page.

What four decades of Thymosin Alpha-1 research actually show

Allan Goldstein and colleagues isolated Thymosin Alpha-1 from calf thymus in 1977 and worked out its full sequence — a 28-amino-acid peptide with an acetyl cap on one end that the molecule needs to work ^[1]. The synthetic drug version, thymalfasin, is an exact copy of that sequence. In the body, the peptide is cut from a larger parent protein called prothymosin alpha.

It works at the meeting point of innate immunity (the body's fast, general defenses) and adaptive immunity (the slower, targeted response). It signals through pattern-sensing receptors — Toll-like receptors TLR2 and TLR9 — on dendritic cells, helping those cells mature and present targets to T-cells, which then expand and shift toward a Th1 (cell-killing) response ^[5]. At the same time it can switch on an enzyme called IDO that builds a calming, regulatory layer — so the peptide both restores tired immunity and damps overreaction ^[5]. That two-sided design is the single most distinctive thing about it, and it is why the same molecule turns up in studies of weakened immunity and, separately, as a partner to cancer immunotherapy.

The clinical record runs four decades and dozens of trials across chronic hepatitis B and C, sepsis, COVID-19, and cancer-adjuvant settings ^[4]. A comprehensive review reports the synthetic peptide is approved in more than 35 countries and is usually well tolerated, with mild injection-site irritation the most common adverse effect ^[4]. Read the full Thymosin Alpha-1 research digest for the study-by-study detail.

Where the evidence is strong — and where it is not

Be precise where the data is precise, honest where it is not. In chronic viral hepatitis and as an immune-restorative add-on, the signal is most consistent, and a comprehensive review across four decades reports the peptide is usually well tolerated, with mild injection-site irritation the most common complaint ^[4].

In sepsis, the story is a caution. An earlier multicentre trial (ETASS, 361 patients) found 28-day mortality of 26.0% with the peptide versus 35.0% in controls — about a 9-point gap that did not reach statistical significance ^[2]. Then the phase-3 TESTS trial (1,106 adults, 2025) — larger and more rigorous — found no significant difference: 23.4% versus 24.1%, hazard ratio 0.99 ^[3]. The largest, best-designed sepsis trial to date was null, and it tempers the earlier hopeful numbers.

In severe COVID-19, a retrospective review of 76 patients linked treatment to lower mortality (11.11% versus 30.00%) and to restored T-cells in patients with severe lymphocytopenia (very low immune-cell counts) ^[6] — promising, but retrospective and not the final word.

What this site is

This is an editorial digest. It reads the peer-reviewed Thymosin Alpha-1 literature, summarizes it in plain English, and cites every quantitative claim back to its study. It is not a clinic and it sells nothing. Throughout, doses appear only as research data — what was given to which population by which route — never as instructions. Browse the Thymosin Alpha-1 effects page for the human-experience layer, the research digest for the mechanism and trials, or the full Thymosin Alpha-1 references list. A note on identity: Thymosin Alpha-1 is constantly confused with other thymic peptides — it is a different molecule from thymosin beta-4 (TB-500), thymulin, thymopentin, thymalin, and its own precursor prothymosin alpha. The thymosin alpha 1 peptide page keeps them apart.